Dose escalation trial of cloretazine (VNP40101M) and hematopoietic cell transplantation for patients with selected, poor-prognosis hematologic malignancies.

Trial Profile

Dose escalation trial of cloretazine (VNP40101M) and hematopoietic cell transplantation for patients with selected, poor-prognosis hematologic malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Fludarabine; Laromustine
  • Indications Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Planned end date changed from 1 Aug 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top